Effectiveness of Routine Intensive CA125 Monitoring in Ovarian Cancer
Not Applicable
Recruiting
- Conditions
- Neoplasms
- Registration Number
- KCT0007454
- Lead Sponsor
- ational Cancer Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Female
- Target Recruitment
- 74
Inclusion Criteria
1. Histologically confirmed advanced (FIGO III-IV) ovarian cancer, fallopian tube cancer, and primary peritoneal cancer patients
2. Serum CA125 concentration of 2x35 U/ml or higher before initiation of treatment
3. Patients with complete remission after primary chemotherapy (excluding maintenance therapy)
4. Serum CA125 concentration below normal (upper normal level (UNL) 35U/ml)
5. Patients 18 years of age or older who gave written informed consent to this trial
Exclusion Criteria
1. If there is an additional malignant disease that is currently in progress
2. If there is a history of benign disease accompanied by elevated CA125 before menopause
3. Pregnant women
Study & Design
- Study Type
- Observational Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Rate of early recurrence for which secondary tumor reduction surgery is possible
- Secondary Outcome Measures
Name Time Method Difference between PFS and PFS2, Prediction accuracy of R0 success rate of secondary tumor reduction surgery, Prognostic factors when performing surgery after secondary tumor reduction, Diagnostic accuracy of CA125 EPD diagnostic criteria, Diagnostic accuracy of imaging tests in the early progression of ovarian cancer